UBS Initiates ADARx Pharmaceuticals at Buy
UBS initiated coverage of ADARx Pharmaceuticals with a Buy rating.
Story updates
12:58:14 PM UTC
SquawkNews
Ratings actions from Benzinga: GMT) ADARx Pharmaceuticals Price Target Announced at $38.00/Share by JP MorganRatings actions from Benzinga